With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two ...

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped ...

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S.

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to ...

Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK ...

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...